Ibalizumab

USDailyMed:Ibalizumab J05AX23(WHO) US:℞-onlyEU:Rx-only 680188-33-4N DB12698Y none LT369U66CE D09575Y ChEMBL1743029 209859 Ibalizumab, sold under the brand nameTrogarzo, is a non-immunosuppressive humanisedmonoclonal antibodythat bindsCD4, the primary receptor forHI​‍​​​​​‍​‍‍‍‍​‍‍V,andinhibits HIV from entering cells.It is a post-attachment inhibitor, blocking HIV from binding to theCCR5andCXCR4co-receptors after HIV binds to the CD4 receptor on the surface of a CD4 cell. Post-attachment inhibitors are a subclass of HIV drugs calledentry inhibitors. On March 6, 2018, the U.S.Food and Drug Administration(FDA) approved ibalizumab for multidrug-resistant HIV-1.It is used in combination with other antiretroviral drugs.The U.S.Food and Drug Administration(FDA) considers it to be afirst-in-class medication.